Praxis Precision Medicines overview and recent trading context

Praxis Precision Medicines (PRAX) has attracted fresh attention after a period of steady trading, with recent returns of 2% over the past day, 9.4% over the past week and 22.4% year to date.

The Boston based clinical stage biopharmaceutical company, focused on therapies for central nervous system disorders, last closed at US$350.60, giving it a market value of about US$9.6b and placing it firmly in the mid cap growth bracket.

Recent trading has been strong, with share price momentum building over the short term and supported by a very large 1 year total shareholder return and multi year gains that indicate a materially higher long term payoff for investors who stayed invested.

If you are looking beyond a single biopharma story, it could be a good moment to scan for other healthcare related opportunities using Simply Wall St’s screener for 34 healthcare AI stocks

With Praxis trading at US$350.60 on no current revenue and a reported net loss of US$326.533m, plus a wide gap to analyst targets and intrinsic value estimates, is the stock mispriced, or is the market already baking in future growth?

Most Popular Narrative: 21.9% Undervalued

Praxis Precision Medicines' most followed narrative points to a fair value of about $449.13 per share, compared with the latest close at $350.60, highlighting a sizeable gap the market has not closed yet.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

Want to see what kind of revenue ramp, margin shift and earnings profile this narrative is baking in, and how that filters into the $449 fair value? The full story breaks down the projected move from deep losses to profitability, the required earnings power a few years out and the rich multiple that would need to hold for that price to stack up.

Result: Fair Value of $449.13 (UNDERVALUED)

However, this upbeat story still hinges on successful late stage trials and broad physician uptake, so any clinical setbacks or slower adoption could quickly challenge that 21.9% undervalued case.

Next Steps

With such a strong narrative on both risks and rewards, do you want to rely on others’ opinions or build your own view while sentiment is still forming? Start by weighing the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Praxis has sharpened your curiosity, do not stop here. A broader watchlist can surface opportunities you would miss by focusing on a single stock.

• Spot potential bargains early by scanning 46 high quality undervalued stocks that pair solid fundamentals with appealing pricing.
• Prioritise resilience by checking 65 resilient stocks with low risk scores that score well on quality and risk controls.
• Hunt for tomorrow's standouts by reviewing the screener containing 22 high quality undiscovered gems before they hit everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.